Compare Applovin Corporation (APP) vs BioNTech SE - ADR (BNTX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Applovin Corporation vs BioNTech SE - ADR — how do they compare? Applovin Corporation trades at $507.11 (market cap $170.31B), while BioNTech SE - ADR trades at $91.14 (market cap $23.14B). The key difference: Applovin Corporation is far larger — about 7.4× BioNTech SE - ADR's market cap, and Applovin Corporation is trading nearer its 52-week high, BioNTech SE - ADR nearer its low. Which is the better fit depends on your goals.
| APP | BNTX | |
|---|---|---|
Market Cap | $170.31B | $23.14B |
Sector | Technology | Health |
52-Week High | $733.60 | $119.34 |
52-Week Low | $335.10 | $83.89 |
Enterprise Value | $171.07B | $6.81B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AppLovin trades at $506.98, down 2.58% today, with a bullish technical setup near pivot point support at $504. The company shows exceptional fundamentals with 59% revenue growth in Q1 2026 and net margins exceeding 64%. Analyst consensus remains strongly bullish with an $644.09 price target, supported by expanding e-commerce advertising share and AI-driven platform growth noted in recent Jefferies research.
The outlook remains positive given consistent earnings beats and projected revenue growth to $6.2B in 2026. Primary risks include premium valuation multiples (P/E 44.09) and competitive pressure in mobile advertising. The stock offers growth exposure but requires monitoring of execution against high expectations.
BNTX trades at $91.49, down 1.6% on the day, with a mixed technical picture showing a bullish overall signal but bearish moving averages. The company reported a net loss of $1.14 billion for 2025, with revenue of $2.87 billion, and is undergoing a strategic shift toward oncology, including a $1 billion share buyback and manufacturing site closures affecting 1,860 jobs. Analyst consensus is strongly bullish with a $129.67 price target.
The outlook hinges on BioNTech's transition from COVID-19 vaccine dependency to oncology pipeline success. Opportunities include a strong cash position of $16.78 billion and promising clinical data, but risks involve execution challenges, sustained losses, and competitive pressures in the biotech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Applovin Corporation
AppLovin provides a software platform for mobile app developers to market, monetize, and analyze their apps. Its AI-powered tools help developers grow their business by connecting them with global advertising networks.
Read more on APP →About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →
